Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 0525 • ACR Convergence 2020
Epidemiology of Thromboembolic Complications Among Hospitalized Patients with Antiphospholipid Syndrome in the United States
Lauren Mathias¹, Aditya Mantha², Kristen Mathias³ and Glenn Ehresmann¹, ¹University of Southern California, Division of Rheumatology, Los Angeles, CA, ²University of Southern California, Department of Medicine, Los Angeles, CA, ³University of Chicago, Department of Medicine, Chicago, IL
Background/Purpose: Antiphospholipid syndrome (APLS) is characterized by arterial and venous thrombosis, often in the setting of an underlying systemic disease. Few studies have described the…
Abstract Number: 1775 • ACR Convergence 2020
Risk Factors for Adverse Pregnancy Outcomes of Women with Positive for Antiphospholipid Antibodies Treated with Conventional Therapies
Hiromi Shimada¹, Risa Wakiya², Mai Mahmound Fahmy Mansour¹, Shusaku Nakashima¹, Mikiya Kato¹, Koichi Sugihara¹, Yusuke Ushio¹, Tomohiro Kameda¹ and Hiroaki Dobashi³, ¹Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University., Kita-gun, Kagawa, Japan, ²Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University., Kagawa, Kagawa, Japan, ³Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: Antiphospholipid antibodies induce several obstetric complications including recurrent spontaneous abortion, preterm birth, intrauterine fetal death. EULAR recommendations for antiphospholipid syndrome (APS) indicates low dose…
Abstract Number: 0526 • ACR Convergence 2020
Patient-Reported Outcomes in Antiphospholipid Syndrome
Julia Weiner¹, Kelsey Gockman¹, Jacqueline Madison¹, Yu Zuo², Emily Briceño¹, Vivek Nagaraja³ and Jason Knight², ¹University of Michigan, Ann Arbor, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³University of Michigan, Ann Arbor, MI
Background/Purpose: PROMIS® (Patient-Reported Outcome Measurement Information System) is a set of person-centered measures that evaluates and monitors the physical, emotional, and social aspects of health.…
Abstract Number: 1792 • ACR Convergence 2020
Platelet-bound C4d Is Associated with an Increased Risk of Arterial and Venous Thromboses in SLE
Yevgeniya Gartshteyn¹, Roberta Vezza Alexander², John Conklin³, Thierry Dervieux⁴ and Anca Askanase⁵, ¹Columbia University College of Physicians and Surgeons, Glen Rock, NJ, ²Exagen Inc, Vista, CA, ³Exagen Inc., Vista, CA, ⁴Prometheus Biosciences Inc, San Diego, CA, ⁵Columbia University College of Physicians and Surgeons, New York, NY
Background/Purpose: Platelet-bound complement activation products (PC4d), defined as PC4d20 net mean fluorescent intensity [MFI], or a thrombotic risk score that includes PC4d, C3 and anti-phosphatidylserine/prothrombin…
Abstract Number: 0527 • ACR Convergence 2020
Rituximab for Refractory Manifestations of the Antiphospholipid Syndrome: A Multicenter Israeli Experience
Nancy Agmon-Levin¹, Mark Berman², Liora Harel³, Merav Lidar⁴, Soad Hajyahia¹ and Daphna Paran⁵, ¹Clinical Immunology, Angioedema and Allergy Unit, Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel, ²Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ³Scheider Children's Medical Center of Israel, Tel Aviv University, Tel Aviv, Israel, Petach Tikva, Israel, ⁴Rheumatology unit, Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Hod Hasharon, Israel, ⁵Department of Rheumatology, Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: The clinical manifestations of the antiphospholipid syndrome (APS) are heterogeneous and related to anti-phospholipid antibodies (aPL). There is some evidence that B cells are…
Abstract Number: 0528 • ACR Convergence 2020
The Complex Relationship Between C4b Binding Protein, Warfarin and Antiphospholipid Antibodies
Giorgia Grosso¹, Kerstin Sandholm², Aleksandra Antovic¹, Iva Gunnarsson¹, Agneta Zickert¹, Anna Vikerfors³, Lennart Truedsson⁴, Maria Bruzelius¹, Bo Nilsson⁵, Kristina Nilsson Ekdahl⁵ and Elisabet Svenungsson¹, ¹Karolinska University Hospital, Stockholm, Sweden, ²Linnaeus Center for Biomaterials Chemistry, Linnaeus University, Kalmar, Sweden, ³Swedish Medical Products Agency, Uppsala, Sweden, ⁴Lunds University, Lund, Sweden, ⁵Uppsala University, Uppsala, Sweden
Background/Purpose: C4b Binding Protein (C4BP) is the main inhibitor of the classical complement pathway. Both β2glycoprotein-I (β2GPI), the main antigen in the antiphospholipid syndrome (APS),…
Abstract Number: 0529 • ACR Convergence 2020
A Prospective Study on the Incidence of a First Thrombo-embolic Event in Patients with Systemic Lupus Erythematosus and Anti-phosphatidylserine/prothrombin Antibodies
Savino Sciascia¹, Massimo Radin¹, Irene Cecchi¹, Daniela Rossi¹ and Dario Roccatello², ¹University of Torino, Torino, Italy, ²S Giovanni Hospital, Univ of Turin, Turin, Italy
Background/Purpose: Prospective data confirming the role of anti-phosphatidylserine/prothrombin antibodies (aPS/PT) in the absence of other aPL tested by β2–glycoprotein I-depend assays are missing.Methods: Since 2015 aPSPT…
Abstract Number: 0530 • ACR Convergence 2020
Pediatric APS: Clinical Features, Therapeutic Interventions, and Damage in a Series of 22 Cases
Jacqueline Madison¹, Kelsey Gockman¹ and Jason Knight², ¹University of Michigan, Ann Arbor, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Pediatric antiphospholipid syndrome (APS) is a thromboinflammatory disease classically defined by the presence of circulating antiphospholipid antibodies and either thrombotic events or pregnancy morbidity.…
Abstract Number: 0847 • ACR Convergence 2020
Impact of Hydroxychloroquine Treatment on Immunologic Markers in SLE Depends on Ethnicity
Laurence Magder¹, Daniel Goldman² and Michelle Petri², ¹University of Maryland, Baltimore, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: SLE patients with certain immunological markers (i.e., anti-DNA, low complement) are at higher risk of lupus nephritis and those with antiphospholipid antibodies are at…
Abstract Number: 0938 • ACR Convergence 2020
Low Preconceptional Complement Level Is Related with an Adverse Obstetric Outcome in a Multicentric Cohort of Pregnancy in Patients with APS and aPL Positivity
Cecilia Nalli¹, Daniele Lini², Laura Andreoli², Francesca Crisafulli², Micaela Fredi², Maria Grazia Lazzaroni², Victoria Bitsadze³, Antonia Calligaro⁴, Valentina Canti⁵, Roberto Caporali⁶, Francesco Carubbi⁷, Cecilia Chighizola⁸, Paola Conigliaro⁹, Caterina De Carolis¹⁰, Teresa Del Ross⁴, Maria Favaro⁴, Maria Gerosa¹¹, Annamaria Iuliano¹², Jamilya Khizroeva³, Alexander Makatsariya³, Pierlugi Meroni¹³, Marta Mosca¹⁴, Melissa Padovan¹⁵, Roberto Perricone⁹, Patrizia Rovere-Querini¹⁶, Gian Domenico Sebastiani¹², Chiara Tani¹⁴, Marta Tonello⁴, Dina Zucchi¹⁴, Franco Franceschini¹⁷ and Angela Tincani², ¹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia, Brescia, Lombardia, Italy, ²Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia, Brescia, Lombardia, Italy, ³Department of Obstetrics and Gynecology of I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia, ⁴Rheumatology Unit, Department of Medicine, University Hospital of Padua, Padua, Italy, ⁵Immunology, Rheumatology, Allergology and Rare Disease-IRCCS San Raffaele Hospital, Laboratory of Autoimmunity and vascular inflammation San Raffaele, Milan, Italy, ⁶Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ⁷Department of Biotechnological and Applied Clinical Science, Rheumatology Unit, School of Medicine, University of L'Aquila, L'Aquila, Italy, ⁸Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; Experimental Laboratory of Immunorheumatological Researches, Istituto Auxologico Italiano, Milan, Italy, ⁹Rheumatology, Allergology and Clinical Immunology, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, Italy, ¹⁰Polymedical Center for Prevention of Recurrent Spontaneous Abortion, Rome, Italy, ¹¹Division of Rheumatology, Department of Clinical Sciences and Community Health, Ospedale Gaetano Pini, University of Milan, Milan, Italy, ¹²Rheumatology Unit, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy, ¹³Division of Rheumatology, ASST.G Pini, Department of Clinical Sciences and Community Health, University of Milan and Istituto Auxologico Italiano, Milan, Italy, ¹⁴Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹⁵UO e Sezione di Reumatologia, Dipartimento di Scienze Mediche, Universita' degli Studi di Ferrara, Ferrara, Italy, ¹⁶Unit of Immunology, Rheumatology, Allergy and Rare Diseases, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, Milan, Italy, ¹⁷Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy
Background/Purpose: The role of complement in the aPL related pathology has been widely studied in animal models. aPL can induce fetal loss in experimental animals but…
Abstract Number: 1261 • ACR Convergence 2020
Antiphospholipid Patterns Predict the Risk of Thrombosis in Systemic Lupus Erythematosus
Selcan Demir¹, Jessica Li², Laurence Magder³ and Michelle Petri⁴, ¹Hacettepe University Faculty of Medicine, Ankara, Ankara, Turkey, ²Johns Hopkins University, Baltimore, MD, ³University of Maryland, Baltimore, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Antiphospholipid syndrome (APS) has been classified as the development of venous and/or arterial thromboses, and/or pregnancy morbidity, in the presence of persistently raised levels…
Abstract Number: 0429 • ACR Convergence 2020
Prothrombotic Antiphospholipid Antibodies in COVID-19
Yu Zuo¹, Shanea Estes², Alex Ghandi³, Srilakshmi Yalavarthi³, Ramadan Ali³, Shi Hui³, Gautam Sule³, Kelsey Gockman³, Jacqueline Madison³, Melanie Zuo³, Wrenn Woodard³, Sean Lezak³, Njira Lugogo³, Yogendra Kanthi⁴ and Jason Knight¹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³University of Michigan, Ann Arbor, ⁴Division of Cardiovascular Medicine, Ann Arbor
Background/Purpose: Patients with coronavirus disease 19 (COVID-19) are at high risk for thrombosis of arteries and veins. At the same time, COVID-19 lung histopathology has…
Abstract Number: 1262 • ACR Convergence 2020
Single LAC Positivity versus Double and Triple Positivity for Thrombosis in SLE
Selcan Demir¹, Jessica Li², Laurence Magder³ and Michelle Petri⁴, ¹Hacettepe University Faculty of Medicine, Ankara, Ankara, Turkey, ²Johns Hopkins University, Baltimore, MD, ³University of Maryland, Baltimore, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose:Antiphospholipid syndrome (APS) is classified as the development of venous and/or arterial thromboses, and pregnancy morbidity, in the presence of antiphospholipid antibodies (aPL); lupus anticoagulant,…
Abstract Number: 0519 • ACR Convergence 2020
Thrombotic and Obstetric Associations of Non-Criteria Antiphospholipid Immunoassays That Detect Antibodies to Neutral and Negatively-Charged Phospholipid
Rohan Willis¹, E Nigel Harris², Vijaya Murthy³, Zurina Romay-Penabad¹, Alvaro Schleh⁴, Monica Smikle², Karel De Ceulaer², Anne Tebo⁵, Troy Jaskowski⁶, Marta Guerra⁷, David Ware Branch⁸, Jane Salmon⁷, Michelle Petri⁹ and Emilio Gonzalez¹, ¹University of Texas Medical Branch, Galveston, TX, ²University of the West Indies, Kingston, Jamaica, ³University of Texas Medical Branch, League City, TX, ⁴Antiphospholipid Standardization Laboratory, GALVESTON, TX, ⁵Department of Pathology, University of Utah, Salt Lake City, ⁶ARUP Laboratories, Salt Lake City, UT, ⁷Hospital for Special Surgery, New York, NY, ⁸University of Utah, Salt Lake City, ⁹Johns Hopkins University School of Medicine, Baltimore
Background/Purpose: Criteria antiphospholipid (aPL) antibodies that identify antiphospholipid syndrome (APS) patients, anticardiolipin (aCL) and anti-β2glycoprotein-I (anti-β2GPI), have demonstrated inconsistent specificity and sensitivity in this regard…
Abstract Number: 1447 • ACR Convergence 2020
Vitamin D Deficiency Enhances Antiphospholipid Antibody-Mediated Thrombosis in a Passive Immunization Mouse Model
Rohan Willis¹, Karen Roye-Green², Zurina Romay-Penabad¹, Elizabeth Papalardo¹, Alvaro Schleh³, Vijaya Murthy⁴, Monica Smikle² and Emilio Gonzalez¹, ¹University of Texas Medical Branch, Galveston, TX, ²University of the West Indies, Kingston, Jamaica, ³Antiphospholipid Standardization Laboratory, GALVESTON, TX, ⁴University of Texas Medical Branch, League City, TX
Background/Purpose: Abnormal vitamin D levels occur frequently in antiphospholipid (APS) patients and are correlated with thrombosis. It remains unclear however if vitamin D deficiency observed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].